From: miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma
Clinicopathological features | No. of cases (N = 186) | miR-663a expression | P-value | |
---|---|---|---|---|
High (n %) | Low (n %) | |||
Age (year) | ||||
≥50 | 156 | 80(86.0%) | 76(81.7%) | 0.550 |
< 50 | 30 | 13(14.0%) | 17(18.3%) | |
Gender | ||||
Male | 160 | 78(83.9%) | 82(88.2%) | 0.527 |
Female | 26 | 15(16.1%) | 11 (11.8%) | |
HBsAg status | ||||
Positive (+) | 132 | 63(67.7%) | 69(74.2%) | 0.419 |
Negative (−) | 54 | 30(32.3%) | 24(25.8%) | |
Cirrhosis | ||||
YES | 131 | 64(68.8%) | 67(72%) | 0.748 |
NO | 55 | 29(31.2%) | 26(28%) | |
AFP (ng/ml) | ||||
≥7 | 109 | 57(61.3%) | 52(55.9%) | 0.552 |
< 7 | 77 | 36(38.7%) | 41(44.1%) | |
PVTT | ||||
YES | 37 | 15(16.1%) | 22(23.7%) | 0.270 |
NO | 149 | 78(83.9%) | 71(76.3%) | |
Tumor size(cm) | ||||
≥5 | 111 | 48(51.6%) | 63(67.7) | 0.036* |
< 5 | 75 | 45(48.4%) | 30(32.3) | |
Tumor number | ||||
Single | 38 | 28(30.1%) | 10(10.8%) | 0.002* |
Multiple | 148 | 65(69.9%) | 83(89.2%) | |
Tumor differentiation | ||||
Well-moderate | 151 | 72(86.0%) | 79(84.9%) | 0.129 |
Poor | 35 | 21(14.0%) | 14(15.1%) | |
TNM stage (Edition 7th) | ||||
I | 118 | 62(66.7%) | 56(60.2%) | 0.341 |
II | 36 | 17(18.3%) | 19(20.4%) | |
III | 32 | 14(15.0%) | 18(19.4%) |